Jessica Nazzaro
Obstetrics & Gynecology · Dover, OHNPI 1982050555
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 25.8% of the total. Reporting peaked in 2020 at $191 and has fallen 72.3% since, to $53 in 2024. That places this record below the midpoint for obstetrics & gynecology clinicians in OH, where the typical reported total is $509.
Across 15 payments — averaging $22.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$89
- Merck$80
- Channel Medsystems, Inc.$53
- Sage Therapeutics, LLC$30
- Organon$26
- Pacira Pharmaceuticals Incorporated$24
- plus $44 from 3 others
What the payments were for
- Food & beverage$345100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 6 | $89 |
| Merck | 2 | $80 |
| Channel Medsystems, Inc. | 1 | $53 |
| Sage Therapeutics, LLC | 1 | $30 |
| Organon | 1 | $26 |
| Pacira Pharmaceuticals Incorporated | 1 | $24 |
| Boston Scientific | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Clovis Oncology, Inc. | 1 | $12 |
How this compares
$345 in reported general payments places this provider in the 40th percentile of 1,376 obstetrics & gynecology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZafemyNorelgestromin/Ethin.Estradiol | 13 | $1,158 |
| Oxybutynin Chloride ErOxybutynin Chloride | 14 | $442 |
| Estradiol | 14 | $374 |
| MicrogestinNorethindrone Ac/Eth Estradiol | 11 | $152 |
| Mono-LinyahNorgestimate-Ethinyl Estradiol | 11 | $68 |
| Medroxyprogesterone Acetate | 12 | $67 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Dover
- Samir AhujaMentor$430K
- Burton BrodskySylvania$202K
- Sandor MecsSteubenville$190K
- David SchwartzCincinnati$169K
- Erin OlahColumbus$97K
- David PortmanColumbus$94K
- Anita SomaniColumbus$93K
- Lorie Thomas-SchultzFindlay$92K
- Oluwatosin GojeCleveland$81K
- Gerard ReillyCincinnati$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.